Compared to other 18F-labeled PSMA agents, the latter finding of less hepatic uptake may play a role for an increased detection rate of liver lesions attributable to PCa 14 and may aid in the identification of high retroperitoneal lymph nodes. The gene discussed is FOLH1; the disease is posterior cortical atrophy.